Document ID: chunk:federal_register_of_legislation:F2025L00212:clause:1_2933
Version: federal_register_of_legislation:F2025L00212
Segment Type: clause
Provision Reference: sch 1 cl 2933
Character Range: 1339857–1341122

2933                                      LARIX ARABINOGALACTAN                                                                         A, E      The concentration of polysaccharides in the ingredient must be greater than or equal to 85%.
                                                                                                                                                  The ingredient must be derived from Larix occidentalis or Larix larcinia.
                                                                                                                                                  Only for use in oral medicines or topical medicines for dermal application, and not to be included in topical products intended for use in the eye.
                                                                                                                                                  The maximum recommended daily dose of Larix arabinogalactan in oral medicines must not be more than 15 grams.
                                                                                                                                                  The concentration of Larix arabinogalactan in topical medicines for dermal application must not exceed 5.0%.